Materials and methods for treating diseases caused by genetic disorders using aminoglycosides and derivatives thereof which exhibit low nephrotoxicity
Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health.
1. A method of treating a genetic disease in a patient having a stop codon in the open reading frame of an otherwise functional gene comprising administering to the patient a composition comprising native gentamicin that has been enriched with a C2 congener of gentamicin.
2. The method of claim 1 , wherein the patient has kidney disease or a preexisting risk factor for developing kidney disease.
3. The method of claim 1 , wherein the stop codon is UAAC, UAGC, UGAC, UAAG, UAGG, UGAG, UAAU, UAGU, UGAU, UAAA, UAGA, or UGAA.
4. The method of claim 3 , wherein the stop codon is UAGC.
5. The method of claim 1 , wherein the patient is an animal.
6. The method of claim 1 , wherein the patient is a human.
7. The method of claim 1 , comprising administering about 3 mg/kg body weight to about 6 mg/kg body weight gentamicin per day.
8. The method of claim 1 , wherein administering comprises injecting the composition.
9. The method of claim 8 , wherein the composition is administered intramuscularly or intravenously.
10. A method of treating Duchenne muscular dystrophy, cystic fibrosis, Hurler's syndrome, or Becker muscular dystrophy in a patient, comprising administering to the patient a composition comprising native gentamicin that has been enriched with a C2 congener of gentamicin.
11. The method of claim 10 , wherein the patient is an animal.
12. The method of claim 10 , wherein the patient is a human.
13. The method of claim 10 , comprising administering about 3 mg/kg body weight to about 6 mg/kg body weight gentamicin per day.
14. The method of claim 10 , wherein administering comprises injecting the composition.
15. The method of claim 14 , wherein the composition is administered intramuscularly or intravenously.
16. The method of claim 10 , wherein the patient has Duchenne muscular dystrophy.
17. The method of claim 10 , wherein the patient has cystic fibrosis.
18. The method of claim 10 , wherein the patient has Hurler's syndrome.
19. The method of claim 10 , wherein the patient has Becker muscular dystrophy.
20. The method of claim 1 , wherein the patient has Duchenne muscular dystrophy.
21. The method of claim 1 , wherein the patient has cystic fibrosis.
22. The method of claim 1 , wherein the patient has Hurler's syndrome.
23. The method of claim 1 , wherein the patient has Becker muscular dystrophy.